The Medicines Patent Pool (MPP) will take part in AIDS 2026, the world’s leading conference on HIV and AIDS, bringing together policymakers, researchers, civil society, communities, and industry to share the latest scientific advances and discuss global responses to the epidemic.
Held every two years, the International AIDS Conference serves as a key platform to shape policy, accelerate innovation, and strengthen collaboration across sectors to improve prevention, treatment, and care.
At AIDS 2026, MPP will contribute to these efforts by highlighting how voluntary licensing and partnerships can help translate innovation into equitable access to HIV medicines, particularly in low- and middle-income countries. Through its participation—including a satellite session, booth activities, and scientific presentations—MPP will engage with partners to explore how new and existing treatment options can better reach diverse patient populations and deliver real-world impact.
Title: Beyond TLD: Optimising the use of newly-recommended HIV treatment options for diverse patient needs in Latin America and the Caribbean From global recommendations to implementation
Date & time: Tuesday, 28 July 2026 · 18:00–19:30 (BRT) Location: Room 205 and online Convened by MPP, PAHO and Unitaid More information on the AIDS2026 website
MPP, in collaboration with the Pan American Health Organization (PAHO) and Unitaid, will convene a satellite session focused on the evolving HIV treatment landscape.
Session overview
While TLD remains the most used HIV treatment globally, a growing range of non-TLD regimens — including TAF-based regimens, oral dual therapy, and long-acting dual injectable treatments — are now recommended by WHO offering important opportunities to optimize treatment for different populations. However, awareness of these options and of their access pathways remains uneven, and their implementation varies widely across regions. In Latin America and the Caribbean, countries are exploring treatment simplification and cost reduction opportunities that oral dual therapy offers, in particular as a strategy to reduce long-term toxicity from tenofovir in settings where access to generic TAF-based regimens is limited. There is also interest in emerging treatments, such as long-acting injectable cabotegravir and rilpivirine. Given how widespread and affordable TLD has become, ensuring sustainable procurement and equitable access remains a central consideration in exploring any of these options.
This session will provide a global overview of the evolving landscape of non-TLD antiretroviral regimens and discuss how these innovations can translate into real impact for people living with HIV. A regional focus on Latin America and the Caribbean will highlight implementation opportunities and challenges, including from an access and equity lens.
Key speakers
MPP will be present throughout the conference at Booth #717 in the exhibition area.
We will co-host discussions and informal sessions with partners, including on access to paediatric HIV medicines and community-centred approaches to implementation. More information soon!
MPP will also present new research at the conference:
“Access to quality affordable WHO-recommended non-TLD first-line HIV treatment – TAF-based, dual oral,and long-acting – regimens in LMICs: Mapping the landscape of MPP-licensed products” TUPEF635 – To be presented by Sébastien Morin on Tuesday 28 July, 12:00-13:00 Authors: Sébastien Morin, Lobna Gaayeb, Marie Lévy, Manuele Piccoli, Shambavi Warerkar Pai, Aditi Das, Amina Larbi, Esteban Burrone
“From licensing to rolling out at scale: Trends in affordable access to DTG-based HIV treatments in low- and middle-income countries, 2014-2025” THPEE510 – To be presented by Sébastien Morin on Thursday 30 July, 12:00-13:00 Authors: Maneesha Ranaut, Sébastien Morin, Esteban Burrone, Aditi Das
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.